ZA946529B - Phenylalkanolamine derivatives - Google Patents

Phenylalkanolamine derivatives

Info

Publication number
ZA946529B
ZA946529B ZA946529A ZA946529A ZA946529B ZA 946529 B ZA946529 B ZA 946529B ZA 946529 A ZA946529 A ZA 946529A ZA 946529 A ZA946529 A ZA 946529A ZA 946529 B ZA946529 B ZA 946529B
Authority
ZA
South Africa
Prior art keywords
hydrogen
hydroxy
diastereomer
formula
aryl lower
Prior art date
Application number
ZA946529A
Other languages
English (en)
Inventor
Erno Mohacsi
Jay Philip O'brien
Original Assignee
Hoffman La Roche A G F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffman La Roche A G F filed Critical Hoffman La Roche A G F
Publication of ZA946529B publication Critical patent/ZA946529B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Solid Fuels And Fuel-Associated Substances (AREA)
  • Table Devices Or Equipment (AREA)
  • Fats And Perfumes (AREA)
  • Organic Insulating Materials (AREA)
  • Indole Compounds (AREA)
ZA946529A 1993-09-02 1994-08-26 Phenylalkanolamine derivatives ZA946529B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11638593A 1993-09-02 1993-09-02

Publications (1)

Publication Number Publication Date
ZA946529B true ZA946529B (en) 1995-03-02

Family

ID=22366865

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA946529A ZA946529B (en) 1993-09-02 1994-08-26 Phenylalkanolamine derivatives

Country Status (22)

Country Link
EP (1) EP0648744B1 (de)
JP (1) JP2610784B2 (de)
KR (1) KR100360954B1 (de)
CN (1) CN1061035C (de)
AT (1) ATE162520T1 (de)
AU (1) AU7149794A (de)
BR (1) BR9403418A (de)
CA (1) CA2129771C (de)
CZ (1) CZ210694A3 (de)
DE (1) DE69408078T2 (de)
DK (1) DK0648744T3 (de)
ES (1) ES2113585T3 (de)
FI (1) FI107607B (de)
GR (1) GR3026622T3 (de)
HU (1) HUT70558A (de)
IL (1) IL110812A0 (de)
NO (1) NO943231L (de)
NZ (1) NZ264320A (de)
PL (1) PL304863A1 (de)
RU (1) RU94031753A (de)
TW (1) TW281670B (de)
ZA (1) ZA946529B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693804A (en) * 1994-11-17 1997-12-02 Molecular Geriatrics Corporation Substituted 1-aryl-3-piperazin-1'-yl propanones
US6214994B1 (en) 1997-04-21 2001-04-10 Molecular Geriatrics Corporation Certain substituted 1-aryl-3-piperazin-1′-yl propanones
US5658909A (en) * 1994-11-17 1997-08-19 Molecular Geriatrics Corporation Certain substituted 1-aryl-3-piperazin-1'-yl propanones to treat Alzheimer's Disease
FR2742051B1 (fr) * 1995-12-06 1998-02-06 Synthelabo Utilisation de composes ayant une affinite pour le site de liaison du (3h)ifenprodil pour la fabrication de medicaments utiles dans la prevention et le traitement des neuropathies
ZA9610736B (en) * 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
BR9814867A (pt) 1997-10-24 2000-10-03 Warner Lambert Co Método para tratar discinesias relacionadas a doenças ou induzidas por drogas
GB9804885D0 (en) 1998-03-06 1998-04-29 Merck Sharp & Dohme Therapeutic combination
DE19812331A1 (de) 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
DK1409477T3 (da) 2001-07-24 2008-12-08 Richter Gedeon Nyrt Piperdinderivater som NMDA receptorantagonister
WO2005030720A1 (ja) 2003-09-25 2005-04-07 Shionogi & Co., Ltd. Ｎｍｄａ受容体拮抗作用を有するピペリジン誘導体
BR112014012167A2 (pt) 2011-11-22 2017-05-30 The Regents Of The Univ Of Calefornia métodos para tratar um indivíduo, um evento isquêmico, métodos para aumentar a razão de níveis de adiponectina e os níveis de adiponectina, e, cisteamina, derivado de cisteamina, derivado de cistamina
RU2649406C1 (ru) * 2017-09-21 2018-04-03 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) 3-n-замещенные борнилпропионаты, используемые в качестве ингибиторов вируса марбург

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4261285A (en) * 1984-06-01 1985-12-05 Tokyo Tanabe Company Limited 1-propanone derivatives
DE3433036A1 (de) * 1984-09-08 1986-03-20 Basf Ag, 6700 Ludwigshafen Piperidinderivate und diese enthaltende fungizide sowie verfahren zur bekaempfung von pilzen
EP0398578B1 (de) * 1989-05-17 1997-03-12 Pfizer Inc. 2-Piperidino-1-alkanol-Derivate als antiischemische Wirkstoffe
US4940789A (en) * 1989-10-10 1990-07-10 American Home Products Corporation 10,11-dihydro-5-alkyl-12-substituted-10,5-(iminomethano)-5H-dibenzo[a,d]cycloheptenes as neuroprotectant agents
WO1992006957A1 (en) * 1990-10-15 1992-04-30 Fisons Corporation 2-phenyl-and 2-thienyl-(2)-piperidine derivatives having neuroprotective properties
SE9003652D0 (sv) * 1990-11-15 1990-11-15 Astra Ab New heterocyclic compounds

Also Published As

Publication number Publication date
GR3026622T3 (en) 1998-07-31
ATE162520T1 (de) 1998-02-15
JP2610784B2 (ja) 1997-05-14
JPH0782250A (ja) 1995-03-28
NZ264320A (en) 1996-02-27
CA2129771A1 (en) 1995-03-03
CA2129771C (en) 2006-03-21
CN1105990A (zh) 1995-08-02
FI944044A (fi) 1995-03-03
AU7149794A (en) 1995-03-16
HUT70558A (en) 1995-10-30
TW281670B (de) 1996-07-21
EP0648744B1 (de) 1998-01-21
KR100360954B1 (ko) 2003-04-16
KR950008481A (ko) 1995-04-17
FI944044A0 (fi) 1994-09-02
NO943231D0 (no) 1994-09-01
CN1061035C (zh) 2001-01-24
DE69408078D1 (de) 1998-02-26
DE69408078T2 (de) 1998-07-09
IL110812A0 (en) 1994-11-11
BR9403418A (pt) 1996-09-03
ES2113585T3 (es) 1998-05-01
CZ210694A3 (en) 1995-08-16
NO943231L (no) 1995-03-03
EP0648744A1 (de) 1995-04-19
RU94031753A (ru) 1996-07-20
DK0648744T3 (da) 1998-09-21
PL304863A1 (en) 1995-03-06
HU9402479D0 (en) 1994-10-28
FI107607B (fi) 2001-09-14

Similar Documents

Publication Publication Date Title
TW281670B (de)
TW290546B (de)
HUT59109A (en) Process for producing hydroxymethyl-(methylenecyclopentyl)-purines and -pyrimidines, their pharmaceutically acceptable salts and pharmaceutical compositions comprising same
GB8826595D0 (en) Active compounds
HK1012341A1 (en) Pyrrolocarbazole
NZ244587A (en) 1-phosphonomethyl benzimidazole derivatives and pharmaceutical compositions thereof
HUT54362A (en) Process for producing cumarin derivatives and pharmaceutical compositions containing them
PL312471A1 (en) Benzene derivatives effective in ischaemia diseases
IE893230L (en) Hydrocarbon substituted pyrrolidinones
IL89942A0 (en) Heterotetracyclic lactam derivatives
GR3021399T3 (en) Methanoanthracenes as dopamine antagonists
GR3007219T3 (de)
IL103202A0 (en) Method for treating hypertension
TW275629B (de)
HU904013D0 (en) Process for producing substituted 3-amino-sydnonimine derivatives and pharmaceutical preparatives containing these